We are live on ! Find out more

Vertex Pharmaceuticals

VRTX

Market cap $133B

523.93 USD

-11.24

2.1%

At close Updated Oct 23, 4:00 PM EDT

Pre-market

After hours

523.41

-0.52

0.1%

1 day

-2.1%

5 days

4.79%

1 month

1.47%

3 months

10.75%

6 months

20.42%

Year to date

15.88%

1 year

23.97%

5 years

183.22%

10 years

565.48%

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Employees: 6,400

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.2%

Neutral 36.4%

Negative 10.4%

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals NASDAQ: VRTX outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a.

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

7 healthcare stocks that stand out as investors pay up for the sector

Investors have pushed the healthcare sector to a record high, and some favored stocks have high projected revenue growth rates through 2028.

7 healthcare stocks that stand out as investors pay up for the sector

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

The Motley Fool

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generates massive free cash flow while successfully navigating the loss of exclusivity for its top-selling drug. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into gene editing and pain management.

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Vertex Appoints Daniel Brennan to its Board of Directors

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific's Executive Vice President, Chief Fi.

Vertex Appoints Daniel Brennan to its Board of Directors

Zacks Investment Research

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

The Motley Fool

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

See News Rankings

Price charts implemented using Lightweight Charts™